Pharmadrug Inc. (PHRX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.33 Million CAD | 44.58% |
| 2022 | -2.34 Million CAD | 36.99% |
| 2021 | -4.2 Million CAD | -51.66% |
| 2020 | -4.28 Million CAD | 41.58% |
| 2019 | -5.72 Million CAD | -354.0% |
| 2018 | -2.39 Million CAD | -732.68% |
| 2017 | 681.1 Thousand CAD | -101.61% |
| 2016 | -7.55 Million CAD | 1091.43% |
| 2015 | -711.12 Thousand CAD | 53.63% |
| 2014 | -2 Million CAD | -571.96% |
| 2013 | -538.25 Thousand CAD | -13.45% |
| 2012 | -202.65 Thousand CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -436.9 Thousand CAD | 96.69% |
| 2024 Q2 | -49.86 Thousand CAD | 88.7% |
| 2023 Q4 | -1.61 Million CAD | -688.84% |
| 2023 Q1 | -206.73 Thousand CAD | 29.86% |
| 2023 Q2 | -283.47 Thousand CAD | -37.12% |
| 2023 Q3 | -204.13 Thousand CAD | 27.99% |
| 2023 FY | - CAD | 4.02% |
| 2022 Q3 | -576.87 Thousand CAD | -10.27% |
| 2022 Q4 | -294.72 Thousand CAD | 48.91% |
| 2022 FY | - CAD | 36.99% |
| 2022 Q1 | -1.26 Million CAD | -29.24% |
| 2022 Q2 | -523.12 Thousand CAD | 58.61% |
| 2021 Q4 | -977.94 Thousand CAD | -1.86% |
| 2021 FY | - CAD | -51.66% |
| 2021 Q2 | -814.73 Thousand CAD | 23.9% |
| 2021 Q3 | -960.1 Thousand CAD | -17.84% |
| 2021 Q1 | -1.07 Million CAD | -180.08% |
| 2020 Q4 | -382.23 Thousand CAD | 54.61% |
| 2020 Q3 | -842.01 Thousand CAD | 16.28% |
| 2020 Q2 | -1 Million CAD | -245.61% |
| 2020 Q1 | -291 Thousand CAD | 89.68% |
| 2020 FY | - CAD | 41.58% |
| 2019 Q3 | -472.79 Thousand CAD | 57.98% |
| 2019 FY | - CAD | -354.0% |
| 2019 Q4 | -2.82 Million CAD | -496.69% |
| 2019 Q2 | -1.12 Million CAD | -94.59% |
| 2019 Q1 | -578.27 Thousand CAD | -1000.65% |
| 2018 Q4 | -52.53 Thousand CAD | 91.74% |
| 2018 FY | - CAD | -732.68% |
| 2018 Q3 | -635.96 Thousand CAD | -1183.83% |
| 2018 Q2 | 58.67 Thousand CAD | 172.73% |
| 2018 Q1 | -80.67 Thousand CAD | -139.96% |
| 2017 Q2 | -23.34 Thousand CAD | 10.11% |
| 2017 Q4 | -33.62 Thousand CAD | -224.56% |
| 2017 Q3 | -10.35 Thousand CAD | 55.62% |
| 2017 FY | - CAD | -101.61% |
| 2017 Q1 | -25.96 Thousand CAD | 51.99% |
| 2016 Q3 | 83.94 Thousand CAD | -98.83% |
| 2016 Q1 | -25.49 Thousand CAD | 62.25% |
| 2016 Q2 | 7.15 Million CAD | 28176.12% |
| 2016 FY | - CAD | 1091.43% |
| 2016 Q4 | -54.08 Thousand CAD | -164.44% |
| 2015 FY | - CAD | 53.63% |
| 2015 Q4 | -67.52 Thousand CAD | -1662.24% |
| 2015 Q3 | -3832.00 CAD | 97.28% |
| 2015 Q2 | -141.09 Thousand CAD | 35.58% |
| 2015 Q1 | -219.03 Thousand CAD | 38.07% |
| 2014 Q3 | -331.19 Thousand CAD | 10.91% |
| 2014 Q1 | -523.78 Thousand CAD | -43.94% |
| 2014 FY | - CAD | -571.96% |
| 2014 Q4 | -353.69 Thousand CAD | -6.79% |
| 2014 Q2 | -371.74 Thousand CAD | 29.03% |
| 2013 Q4 | -363.88 Thousand CAD | 13.36% |
| 2013 Q2 | -26.58 Thousand CAD | 56.73% |
| 2013 Q1 | -61.44 Thousand CAD | -87.88% |
| 2013 FY | - CAD | -13.45% |
| 2013 Q3 | -419.98 Thousand CAD | -1479.64% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q3 | -3531.00 CAD | 78.47% |
| 2012 Q2 | -16.39 Thousand CAD | 82.65% |
| 2012 Q1 | -94.54 Thousand CAD | -7.21% |
| 2012 Q4 | -32.7 Thousand CAD | -826.2% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q4 | -88.18 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aion Therapeutic Inc. | -6.07 Million CAD | 78.02% |
| Ayurcann Holdings Corp. | -2.01 Million CAD | 33.598% |
| Blueberries Medical Corp. | -1.22 Million CAD | -9.267% |
| The BC Bud Corporation | -1.19 Million CAD | -11.622% |
| BioNxt Solutions Inc. | -6.48 Million CAD | 79.413% |
| CordovaCann Corp. | -1.6 Million CAD | 16.698% |
| Christina Lake Cannabis Corp. | -2.62 Million CAD | 49.112% |
| Captor Capital Corp. | 2.42 Million CAD | 155.139% |
| City View Green Holdings Inc. | -2.01 Million CAD | 33.729% |
| 1CM Inc. | 1.31 Million CAD | 201.636% |
| Global Hemp Group Inc. | -24.79 Thousand CAD | -5284.637% |
| Greenway Greenhouse Cannabis Corporation | -2.2 Million CAD | 39.548% |
| IM Cannabis Corp. | -2.79 Million CAD | 52.15% |
| Lobe Sciences Ltd. | -4.4 Million CAD | 69.675% |
| Maple Leaf Green World Inc. | -392.21 Thousand CAD | -240.377% |
| Mountain Valley MD Holdings Inc. | -3.19 Million CAD | 58.189% |
| Nextleaf Solutions Ltd. | 1.14 Million CAD | 216.942% |
| Ovation Science Inc. | -778.83 Thousand CAD | -71.412% |
| Captiva Verde Wellness Corp. | -6.05 Million CAD | 77.956% |
| RAMM Pharma Corp. | -6.3 Million CAD | 78.816% |
| RIV Capital Inc. | -20.28 Million CAD | 93.417% |
| Revive Therapeutics Ltd. | -5.59 Million CAD | 76.139% |
| Red White & Bloom Brands Inc. | -77.59 Million CAD | 98.279% |
| SLANG Worldwide Inc. | -2.95 Million CAD | 54.756% |
| 1933 Industries Inc. | -10.03 Million CAD | 86.694% |
| Red Light Holland Corp. | -5.25 Million CAD | 74.6% |
| Top Strike Resources Corp. | -767.99 Thousand CAD | -73.831% |
| Xebra Brands Ltd. | -1.49 Million CAD | 10.701% |
| Adastra Holdings Ltd. | -1.41 Million CAD | 5.403% |